Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Alkermes

Rank#2484

Market Cap7.62B

CountryIreland

Summary

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

History

Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland with an operational base in Waltham, Massachusetts. Its branches in Ireland, the U.S. and Continental Europe conduct corporate operations, including research and development (R&D), manufacturing, financing, and sales and marketing.

Mission

Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Vision

Alkermes’ vision is to develop, manufacture and commercialize new medications and drug-delivery technologies to address the unmet medical needs of patients.

References

https://en.wikipedia.org/wiki/Alkermes_(company)

https://in.investing.com/equities/alkermes-plc

https://finance.yahoo.com/quote/ALKS/profile?p=ALKS

https://www.comparably.com/companies/alkermes/mission

https://www.crunchbase.com/organization/alkermes

https://sec.report/CIK/0001520262

https://companiesmarketcap.com/

https://www.alkermes.com

Leadership team

Mr. Richard F. Pops (Chairman & CEO)

Mr. Iain Michael Brown (Sr. VP & CFO)

Mr. Blair C. Jackson (Exec. VP & COO)

Products / Services

Biotechnology, Health Care, Pharmaceutical

Number of Employees

1,000 - 20,000

Address

Dublin, Dublin, Ireland

Established

1987-01-01

Company Registration

SEC CIK number: 0001520262

Revenue

$1B+

Traded as

ALKS

Website

https://www.alkermes.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Alkermes

Rank#2484

Market Cap7.62B

CountryIreland

Summary

History

Mission

Vision

Alkermes’ vision is to develop, manufacture and commercialize new medications and drug-delivery technologies to address the unmet medical needs of patients.

References

https://en.wikipedia.org/wiki/Alkermes_(company)

https://in.investing.com/equities/alkermes-plc

https://finance.yahoo.com/quote/ALKS/profile?p=ALKS

https://www.comparably.com/companies/alkermes/mission

https://www.crunchbase.com/organization/alkermes

https://sec.report/CIK/0001520262

https://companiesmarketcap.com/

https://www.alkermes.com

Leadership team

Mr. Richard F. Pops (Chairman & CEO)

Mr. Iain Michael Brown (Sr. VP & CFO)